BDBM251913 US10065961, Compound 11::US10683295, Compound 11::US10941151, Compound 11::US9475814, 11

SMILES C[C@H]1N(CCn2c1nnc2-c1coc(C)n1)C(=O)c1ccc(cc1)-c1cccs1

InChI Key InChIKey=HNHPUPCBAQSHTI-CYBMUJFWSA-N

Data  15 KI  5 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 20 hits for monomerid = 251913   

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMAssay Description:The antagonist activity of compounds of the invention is measured following pre-incubation (3 minutes) of the compound with the cells, followed by ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMAssay Description:NK3: The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vit...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi:  44nMpH: 7.4Assay Description:The ability of compounds of the invention to inhibit the binding of the NK-3 receptor selective antagonist 3H-SB222200 was assessed by an in vitro ra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nM ΔG°: >-6.82kcal/molepH: 7.4 T: 25°CAssay Description:The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nM ΔG°: >-6.82kcal/molepH: 7.4 T: 25°CAssay Description:The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nM ΔG°: >-6.82kcal/molepH: 7.4 T: 25°CAssay Description:The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nM ΔG°: >-6.82kcal/molepH: 7.4 T: 25°CAssay Description:The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Membrane...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: The affinity of compounds of the invention for the NK2 receptor was evaluated in CHO recombinant cells which express the human NK2 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The affinity of compounds of the invention for the NK1 receptor was evaluated in CHO recombinant cells which express the human NK1 receptor. Mem...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK2: Binding assays were performed in a 25 mM HEPES/1 mM CaCl2/5 mM MgCl2/0.5% BSA/10 μg/ml saponin, at pH 7.4. Binding assays consisted of 25 &...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetSubstance-P receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataKi: >1.00E+4nMAssay Description:NK1: The following radioligand: [3H] substance P (PerkinElmer Cat#NET111520) was used in this assay. Binding assays were performed in a 50 mM Tris/5 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataIC50: >3.00E+4nMAssay Description:hERG: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKr current generat...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetTranscriptional regulator ERG(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataIC50: >3.00E+4nMAssay Description:The human Ether-a-go-go Related Gene (hERG) encodes the inward rectifying voltage gated potassium channel in the heart (IKr) which is involved in car...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataIC50:  34nMAssay Description:Changes in intracellular calcium levels are a recognized indicator of G protein-coupled receptor activity. The efficacy of compounds of the invention...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataIC50: >3.00E+4nMAssay Description:The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKf current generated in ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent

TargetNeuromedin-K receptor(Human)
Ogeda

US Patent
LigandPNGBDBM251913(US10065961, Compound 11 | US10683295, Compound 11 ...)
Affinity DataIC50:  34nMAssay Description:The antagonist activity of compounds of the invention is measured following pre-incubation (3 minutes) of the compound with the cells, followed by ad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent